We are pleased to announce that co-founder and Managing Partner Aaron Kantoff has joined the Board of Directors of The Lustgarten Foundation.?Since 1998, the Foundation has been a driving force in major advancements in pancreatic cancer research. To learn more, visit: https://lnkd.in/etnbtjvp
Scion Life Sciences
风险投资与私募股权管理人
New York，NY 1,799 位关注者
Building exceptional companies. Creating transformational medicines.
关于我们
Scion Life Sciences is a life sciences venture capital firm committed to meaningfully improving human health through long-term ownership of clinically transformative therapies. Our team of experienced innovators, company-builders and investors is founding and building exceptional biotechnology companies to discover, develop, and commercialize clinically transformational or curative new medicines. We aim to support impactful and sustainable advancements with a strategic and pragmatic approach to investment and innovation.
- 网站
-
https://www.scionlifesciences.com/
Scion Life Sciences的外部链接
- 所属行业
- 风险投资与私募股权管理人
- 规模
- 2-10 人
- 总部
- New York，NY
- 类型
- 合营企业
地点
-
主要
获取路线
220 E 42nd St
37th / PH Floor
US，NY，New York，10017
Scion Life Sciences员工
动态
-
Aaron Kantoff had the opportunity to sit down with Brad Loncar today for a segment of BiotechTV. Click below to view the full video and please follow our page to learn more about Scion Life Sciences.
???????? ????????: Scion Life Sciences co-founder Aaron Kantoff on coming out of stealth mode and the new $310 million venture fund announced this week. He describes Scion's mission and investment strategy, discusses co-founding RayzeBio, and shares his thoughts on the current state of biotech. Full video: https://lnkd.in/gGkjumdi BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE
-
Thank you to Kyle LaHucik for a great discussion with Managing Partners Aaron Kantoff and Sam Hall. Learn more about Scion in his Endpoints News article out this morning.
Biotech venture firm Scion Life Sciences unveiled Wednesday with $310 million ($60 million above its initial target). With a long investing horizon, it wants to create the next Vertex or Regeneron. “We believe that M&A is not an investment thesis." The trio of founders is focused on forming a small group of biotechs that will commercialize their own treatments and stay independent. More from my interview with Scion Life Sciences' Aaron Kantoff and Sam Hall in Endpoints News: #venturecapital #biotech #lifesciences #drugdevelopment #drugdiscovery #biologics
Scion Life Sciences nabs $310M, with four biotechs already in the works
https://endpts.com
-
We’re thrilled to announce our official launch and the oversubscribed?$310M?closing of our inaugural fund to create and build exceptional #biotech companies. Read today's release to learn more about our mission and investment approach: https://lnkd.in/eY7jz5Zu
-